GlassScriptPhysician profile
Gerard P Varlotta
NPI 1003818584
$6,617.02
in general payments reported to CMS, 2019-2025
26 companies · $614 in 2025
The $614 reported for 2025 was more than what 87% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
See the full distribution for Sports Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $905 · 2021: $978 · 2022: $1,031 · 2023: $1,102 · 2024: $1,127 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,994.15 | 2019-2025 | Ztlido |
| Horizon Therapeutics Plc | $1,357.53 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $671.06 | 2019-2025 | Xtampza |
| Medtronic, INC. | $555.00 | 2023-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Stryker Corporation | $327.01 | 2021-2022 | |
| Almatica Pharma LLC | $213.35 | 2021-2023 | Gralise |
| Allergan, INC. | $210.38 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $164.93 | 2023-2025 | Horizant, Horizant |
| Pfizer INC. | $149.72 | 2020 | |
| Ibsa Pharma INC. | $138.37 | 2020-2025 | Tirosint, Licart, Tirosint |
| Depuy Synthes Sales INC. | $121.54 | 2019-2023 | Orthovisc |
| Assertio Therapeutics, INC. | $120.41 | 2019 | |
| Bioventus LLC | $88.10 | 2019-2023 | Durolane |
| Abbvie INC. | $78.26 | 2022-2023 | Botox |
| Zyla Life Sciences, INC. | $71.92 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $62.33 | 2021 | |
| Djo, LLC | $53.42 | 2023 | Cmf |
| Vertex Pharmaceuticals Incorporated | $51.39 | 2024-2025 | |
| Fidia Pharma USA INC. | $37.97 | 2020-2024 | Hymovis |
| Boston Scientific Corporation | $31.58 | 2020 | |
| Forte Bio-Pharma LLC | $27.70 | 2023 | Prolate, Nalocet |
| Si-Bone, INC. | $27.65 | 2019 | |
| Biodelivery Sciences International, INC. | $18.19 | 2020 | |
| Medtronic USA, INC. | $16.05 | 2019 | |
| Baudax Bio INC. | $14.65 | 2020 | |
| Medline Industries LP | $14.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Varlotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.